Life Science Investing Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer's Disease Agitation
Life Science Investing Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
Life Science Investing Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
Life Science Investing Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Life Science Investing Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
Life Science Investing Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
Life Science Investing Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
